The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA

• Status: Completed
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Topical Brimonidine is a well-established topical antigalucoma, ocular hypotensive therapeutic that has been in use since 1996. Brimonidine stands out among other topical ocular hypotensives in that it has a neuroprotective effect that is independent of IOP reduction. This has been demonstrated in multiple animal and human controlled studies both in vivo and in vitro. The mechanisms proposed so far to account for this neuroprotection focus mainly on molecular level antiapoptotic effects and modulation of some excitatory stimuli like glutamate. In this study we try to test the hypothesis that a positive hemodynamic profile of Brimonidine on ocular blood flow may be responsible at least in part for its unique neuroprotective effects.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fayoum University
• Treatments: Brimonidine Tartrate; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• Primary open angle glaucoma patients.

• Brimonidine naiive.

• Medication naiive or on a fixed antiglaucoma medication for at least a month prior to commencing Brimonidine.

Exclusion Criteria:

• Glaucomas other than primary open angle glaucoma.

• Other comorbid diseses both ocular and systemic that might confound the density and flow measurements ( hypertension, diabetes, vasculitis, MacTel, Uveitis)

• Comorbid diseases that constitute relative or absolute contraindication to Brimonidine ( pregnancy, lactation, bronchial asthma, cardiovascular diseases)

• Prior use of Brimonidine.

• A change in the glaucoma medication regimen within Less than one month at time of presentation.

• Allergy to Brimonidine or related compounds.